The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
A recall which was issued across nine states has now been given the highest risk classification by the federal agency.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval
Medicine may not be an exact science, but precision is crucial for patient care. That’s why the presence of unknown particles in injectable vials of Phenylephrine Hydrochloride prompted a recall by the U.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most were in favor of the change and agreed that, if finalized, the labels would help them make better-informed nutrition choices.
The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with certain patient monitors from Contec and Epsimed and urged healthcare facilities to mitigate those risks.